SynthesisNeurology2013
APOE genotype and MRI markers of cerebrovascular disease: systematic review and meta-analysis.
Synthesis in Neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
109 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- The Impact of Vascular Risk Factors on Cerebral Amyloid Angiopathy: A Cohort Study in Hereditary Cerebral Amyloid Angiopathy and a Systemic Review in Sporadic Cerebral Amyloid Angiopathy.Cerebrovascular diseases (Basel, Switzerland) · 2025Pooled it
- A genome-wide association meta-analysis of all-cause and vascular dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Pooled it
- Pooled it
- Prognostic value of apolipoproteins in COVID-19 patients: A systematic review and meta-analysis.Travel medicine and infectious diseasePooled it
- Hemorrhage Pattern and Amyloid Burden in Cerebral Amyloid Angiopathy.Journal of the American Heart Association · 2026Article
- Chemokines CXCL9 and CCL2 in Relation to Cerebral White Matter Disease, Cognitive Decline, and Dementia: The Northern Manhattan Study.Neurology open access · 2026Article
- Impact of APOE ε4 Genotype Load on Cognitive Function and Lipid Metabolism in Patients With Cerebral Small Vessel Disease.Annals of clinical and translational neurology · 2026Article
- Article
- The dual role of APOE ε4 allele in cerebral small vessel disease: independent genetic effects and effect modification of traditional risk factors.Frontiers in neurology · 2026Article
- Shared Neuroinflammatory Mechanisms Across Dementia Types: An Integrative Review.International journal of molecular sciences · 2025Review
- White matter brain age as a biomarker of cerebrovascular burden in the ageing brain.European archives of psychiatry and clinical neuroscience · 2025Article
- Vascular Dementia: From Pathophysiology to Therapeutic Frontiers.Journal of clinical medicine · 2025Review
- Mediation of the Association BetweenNeurology · 2025Article
- White matter hyperintensity spatial patterns: Risk factors and clinical correlates.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Regional cerebral blood flow reflects both neurodegeneration and microvascular integrity across the Alzheimer's continuum.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Cerebral microvascular changes in healthy carriers of the APOE-ɛ4 Alzheimer's disease risk gene.PNAS nexus · 2024Article
- Associations of Microbleeds and Their Topography With Imaging and CSF Biomarkers of Alzheimer Pathology in Individuals With Down Syndrome.Neurology · 2024Article
- Impact of age and apolipoprotein E ε4 status on regional white matter hyperintensity volume and cognition in healthy aging.Journal of the International Neuropsychological Society : JINS · 2024Article
- Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly.Alzheimer's research & therapy · 2024Article
- A comprehensive analysis of APOE genotype effects on human brain structure in the UK Biobank.Translational psychiatry · 2024Article
49 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
objectiveWe aimed to examine the association of APOE ε genotype with MRI markers of cerebrovascular disease (CVD): white matter hyperintensities, brain infarcts, and cerebral microbleeds.
methodsWe performed a systematic review and meta-analysis of 42 cross-sectional or longitudinal studies identified in PubMed from 1966 to June 2012 (n = 29,965). This included unpublished data from 3 population-based studies: 3C-Dijon, Framingham Heart Study, and Sydney Memory and Ageing Study. When necessary, authors were contacted to provide effect estimates for the meta-analysis.
resultsAPOE ε4 carrier status and APOE ε44 genotype were associated with increasing white matter hyperintensity burden (sample size-weighted z score meta-analysis [meta]-p = 0.0034 and 0.0030) and presence of cerebral microbleeds (meta odds ratio [OR] = 1.24, 95% confidence interval [CI] [1.07, 1.43], p = 0.004, and 1.87 [1.26, 2.78], p = 0.002), especially lobar. APOE ε2 carrier status was associated with increasing white matter hyperintensity load (z score meta-p = 0.00053) and risk of brain infarct (meta OR = 1.41[1.09, 1.81], p = 0.008).
conclusionsAPOE ε4 and APOE ε2 were associated with increasing burden in MRI markers for both hemorrhagic and ischemic CVD. While the association of APOE ε4 with an increased burden of CVD could be partly contributing to the relationship between APOE ε4 and AD, APOE ε2 was associated with MRI markers of CVD in the opposite direction compared to AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.